Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Paolo Calabro
Based on 13 articles published since 2008
||||

Between 2008 and 2019, Paolo Calabrò wrote the following 13 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Guideline A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. 2018

Rossini, Roberta / Tarantini, Giuseppe / Musumeci, Giuseppe / Masiero, Giulia / Barbato, Emanuele / Calabrò, Paolo / Capodanno, Davide / Leonardi, Sergio / Lettino, Maddalena / Limbruno, Ugo / Menozzi, Alberto / Marchese, U O Alfredo / Saia, Francesco / Valgimigli, Marco / Ageno, Walter / Falanga, Anna / Corcione, Antonio / Locatelli, Alessandro / Montorsi, Marco / Piazza, Diego / Stella, Andrea / Bozzani, Antonio / Parolari, Alessandro / Carone, Roberto / Angiolillo, Dominick J / Anonymous911159 / Anonymous921159 / Anonymous931159 / Anonymous941159 / Anonymous951159 / Anonymous961159 / Anonymous971159 / Anonymous981159 / Anonymous991159 / Anonymous1001159 / Anonymous1011159 / Anonymous1021159 / Anonymous1031159 / Anonymous1041159 / Anonymous1051159 / Anonymous1061159 / Anonymous1071159 / Anonymous1081159 / Anonymous1091159 / Anonymous1101159 / Anonymous1111159 / Anonymous1121159 / Anonymous1131159. ·Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy. Electronic address: roberta.rossini2@gmail.com. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Dipartimento Emergenze e Aree Critiche, Ospedale Santa Croce e Carle, Cuneo, Italy. · Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy. · Division of Cardiology, Department of Cardio-Thoracic Sciences, Università degli Studi della Campania "Luigi Vanvitelli," Naples, Italy. · Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda Ospedaliero Universitaria "Policlinico-Vittorio Emanuele, Catania, Italy; Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. · Coronary Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. · Cardiovascular Department, Humanitas Research Hospital, Rozzano, Italy. · U.O.C. Cardiologia, Azienda USL Toscana Sudest, Grosseto, Italy. · Unità Operativa di Cardiologia, Azienda Ospedaliero-Universitaria di Parma, Italy. · U.O.C. Cardiologia Interventistica, Anthea Hospital, GVM Care & Research, Bari, Italy. · Cardiology Unit, Cardio-Thoraco-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy. · Swiss Cardiovascular Centre Bern, Bern University Hospital, Bern, Switzerland. · Degenza Breve Internistica e Centro Trombosi ed Emostasi, Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy. · Department of Immunohematology and Transfusion Medicine, Thrombosis and Hemostasis Center, ASST Papa Giovanni XXIII, Bergamo, Italy. · Department of Anaesthesia and Critical Care, AORN Dei Colli, Naples, Italy. · Dipartimento di Chirurgia Generale, Humanitas Research Hospital and University, Milano, Italy. · Policlinico Vittorio Emanuele di Catania, Catania, Italy. · Chirurgia Vascolare, Università di Bologna, Ospedale Sant'Orsola-Malpighi, Bologna, Italy. · UOC Chirurgia Vascolare, Dipartimento di Scienze Chirurgiche, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. · Dipartimento di Scienze Biomediche per la Salute, Policlinico San Donato IRCCS, University of Milano, Milan, Italy. · Azienda Ospedaliera Universitaria Città della salute e della scienza, Torino, Italy. · Division of Cardiology, University of Florida, College of Medicine-Jacksonville, Jacksonville, Florida. ·JACC Cardiovasc Interv · Pubmed #29519377.

ABSTRACT: Perioperative management of antithrombotic therapy in patients treated with coronary stents undergoing surgery remains poorly defined. Importantly, surgery represents a common reason for premature treatment discontinuation, which is associated with an increased risk in mortality and major adverse cardiac events. However, maintaining antithrombotic therapy to minimize the incidence of perioperative ischemic complications may increase the risk of bleeding complications. Although guidelines provide some recommendations with respect to the perioperative management of antithrombotic therapy, these have been largely developed according to the thrombotic risk of the patient and a definition of the hemorrhagic risk specific to each surgical procedure, key to defining the trade-off between ischemia and bleeding, is not provided. These observations underscore the need for a multidisciplinary collaboration among cardiologists, anesthesiologists, hematologists and surgeons to reach this goal. The present document is an update on practical recommendations for standardizing management of antithrombotic therapy management in patients treated with coronary stents (Surgery After Stenting 2) in various types of surgery according to the predicted individual risk of thrombotic complications against the anticipated risk of surgical bleeding complications. Cardiologists defined the thrombotic risk using a "combined ischemic risk" approach, while surgeons classified surgeries according to their inherent hemorrhagic risk. Finally, a multidisciplinary agreement on the most appropriate antithrombotic treatment regimen in the perioperative phase was reached for each surgical procedure.

2 Review Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. 2018

Gragnano, Felice / Calabrò, Paolo. ·Division of Clinical Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy; Department of Cardiothoracic and Respiratory Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. ·Atherosclerosis · Pubmed #29407597.

ABSTRACT: Despite recent therapeutic advances, there is an unmet need in cardiovascular disease prevention. Clinical trials and meta-analyses have established that LDL-C lowering, particularly by statin therapy, reduces the progression of coronary atherosclerosis and the risk of coronary events. Insufficient LDL-C reduction and high residual risk in a significant proportion of statin-treated patients signify that additional therapies are required to deliver more effective coronary care. Pharmacological inhibition of cholesterol absorption (with ezetimibe) and PCSK9 activity (with evolocumab or alirocumab) provides potentially useful approaches for the therapeutic modulation of LDL-C metabolism in statin-treated patients. In recent trials, combination strategies involving a statin and non-statin agent (ezetimibe or evolocumab) have been shown to promote coronary atherosclerosis regression and improve cardiovascular outcomes in patients with moderate-to-high cardiovascular risk. This review summarizes recent evidence on the effects of dual lipid-lowering therapy on coronary atherosclerosis.

3 Clinical Trial "Full-plastic jacket" with everolimus-eluting Absorb bioresorbable vascular scaffolds: Clinical outcomes in the multicenter prospective RAI registry (ClinicalTrials.gov Identifier: NCT02298413). 2018

Tarantini, Giuseppe / Masiero, Giulia / Fovino, Luca Nai / Mojoli, Marco / Varricchio, Attilio / Loi, Bruno / Gistri, Roberto / Misuraca, Leonardo / Gabrielli, Gabriele / Cortese, Bernardo / Pisano, Francesco / Moretti, Luciano / Tumminello, Gabriele / Olivari, Zoran / Mazzarotto, Pietro / Colombo, Alessandro / Calabrò, Paolo / Nicolino, Annamaria / Tellaroli, Paola / Corrado, Donatella / Durante, Alessandro / Steffenino, Giuseppe / Anonymous2021030. ·Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. Electronic address: giuseppe.tarantini.1@unipd.it. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Interventional Cardiology, A.O. Monaldi, Naples, Italy. · Cardiology Division, A.O. Brotzu, Cagliari, Italy. · Interventional Cardiology, S. Andrea Hospital, La Spezia, Italy. · U.O. Cardiologia-Emodinamica, Ospedale della Misericordia, Grosseto, Italy. · Interventional Cardiology Unit, Azienda Ospedali Riuniti, Ancona, Italy. · Interventional Cardiology, A.O. Fatebenefratelli, Milan, Italy. · Interventional Cardiology, Parini Regional Hospital, Aosta, Italy. · Cardiology Division, Mazzoni Hospital, Ascoli Piceno, Italy. · Cardinal Massaia Hospital, Asti, Italy. · Cardiology Division, Ca' Foncello Hospital, Treviso, Italy. · Interventional Cardiology, Ospedale Maggiore, Lodi, Italy. · Interventional Cardiology Unit, Luigi Sacco Hospital, Milano, Italy. · Division of Cardiology, Department of Cardio-Thoracic Sciences, Second University of Naples, Naples, Italy. · Interventional Cardiology Unit, Santa Corona General Ospital, Pietra Ligure, Italy. · Biostatistics, Epidemiology and Public Health Unit of Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · "Mario Negri" Research Institute, Milano, Italy. · Cardiology Division, Valduce Hospital, Como, Italy. · USD Emodinamica, A.S.O. S.Croce e Carle, Cuneo, Italy. ·Int J Cardiol · Pubmed #29887475.

ABSTRACT: OBJECTIVES: The objective of this study was to investigate mid-term clinical outcomes of patients treated with 'full-plastic jacket' (FPJ) everolimus-eluting Absorb bioresorbable vascular scaffold (BRS) implantation. BACKGROUND: FPJ with BRS may represent an interesting option for patient with diffuse coronary artery disease (CAD), but data on the clinical impact of FPJ using the Absorb BRS are scant. METHODS: FPJ was defined as the implantation of >56 mm of overlapping BRS in at least one vessel. We compared outcomes of patients receiving Absorb FPJ vs. non-FPJ within the multicenter prospective RAI Registry. RESULTS: Out of 1505 consecutive patients enrolled in the RAI registry, 1384 were eligible for this analysis. Of these, 143 (10.3%) were treated with BRS FPJ. At a median follow-up of 649 days, no differences were observed between FPJ and non-FPJ groups in terms of the device-oriented composite endpoint (DoCE) (5.6% vs. 4.4%, p = 0.675) or the patient-related composite endpoint (PoCE) (20.9% vs. 15.9%, p = 0.149). Patients receiving FPJ had higher rates of target vessel repeat revascularization (TVR) (11.2% vs. 6.3%, p = 0.042). In the FPJ group, there was no cardiac death and only one (very late) stent thrombosis (ST) (0.7%). CONCLUSIONS: Mid-term outcomes of a FPJ PCI strategy in the setting of diffuse CAD did not show a significant increase in composite device- and patient-related events, with rates of cardiac death and ST comparable to non-FPJ Absorb BRS implantation. However, these findings are hypothesis generating and requiring further validation.

4 Clinical Trial Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. 2016

Pighi, Michele / Tomai, Fabrizio / Petrolini, Alessandro / de Luca, Leonardo / Tarantini, Giuseppe / Barioli, Alberto / Colombo, Paola / Klugmann, Silvio / Ferlini, Marco / Ormezzano, Maurizio Ferrario / Loi, Bruno / Calabrò, Paolo / Bianchi, Renato Maria / Faggian, Giuseppe / Forni, Alberto / Vassanelli, Corrado / Valgimigli, Marco / Ribichini, Flavio. ·Department of Medicine, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy. michele.pighi@hotmail.it. · Department of Cardiovascular Sciences, European Hospital, Via Portuense, 700, 00149, Rome, Italy. · Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy. · Department of Cardiology and Cardiac Surgery, A. De Gasperis Niguarda Ca' Granda Hospital, Milan, Italy. · Department of Cardiovascular Sciences, IRCCS Foundation, Policlinico San Matteo, Pavia, Italy. · Department of Cardiovascular Sciences, Brotzu Hospital, Cagliari, Italy. · Cardio-thoracic and Respiratory Sciences Department, Second University of Naples, Monaldi Hospital, A.O.R.N. dei Colli, Naples, Italy. · Department of Cardiac Surgery, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy. · Department of Medicine, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy. · Cardialysis, Rotterdam, The Netherlands. ·J Cardiovasc Transl Res · Pubmed #26684009.

ABSTRACT: Cardiac allograft vasculopathy (CAV) is a form of accelerated atherosclerosis, which represents the leading cause of late morbidity and mortality after heart transplantation. The recent bioresorbable vascular scaffold (BVS) technology represents a potential novel therapeutic tool, in the context of CAV, by allowing transient scaffolding and concomitant vessel healing. Eligible subjects will be treated by using the Absorb Everolimus-Eluting BVS (Abbott Vascular, Santa Clara, CA, USA), and evaluated at pre-determined time points, up to 3 years since the index procedure. Both clinical and imaging data will be collected in dedicated case report forms (CRF). All imaging data will be analyzed in an independent core laboratory. The primary aim of the study is to evaluate the angiographic performance at 1 year of second-generation Absorb BVS, in heart transplant recipients affected by CAV.

5 Article Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. 2019

Sasso, Ferdinando Carlo / Pafundi, Pia Clara / Marfella, Raffaele / Calabrò, Paolo / Piscione, Federico / Furbatto, Fulvio / Esposito, Giovanni / Galiero, Raffaele / Gragnano, Felice / Rinaldi, Luca / Salvatore, Teresa / D'Amico, Michele / Adinolfi, Luigi Elio / Sardu, Celestino. ·Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138, Naples, Italy. ferdinandocarlo.sasso@unicampania.it. · Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138, Naples, Italy. piaclara.pafundi@unicampania.it. · University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138, Naples, Italy. · Division of Cardiology, A.O.R.N. Sant'Anna e San Sebastiano, Caserta, Italy. · Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy. · Department of Medicine and Surgery, University of Salerno, Via Allende, 84081, Baronissi, SA, Italy. · Department of Cardiology, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy. · Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini 5, 80131, Naples, Italy. · Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138, Naples, Italy. · Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy. ·Cardiovasc Diabetol · Pubmed #30832662.

ABSTRACT: BACKGROUND: In patients with Normal Glucose Tolerance (NGT) some causes of ischemic heart disease (IHD) were not completely investigated. The role both of metabolic milieu and adipokines in IHD progression was not fully investigated. Our aim was to assess the link between adipokines plasma levels, insulin resistance (IR) and IHD in NGT patients undergoing Percutaneous Coronary Intervention (PCI). METHODS: AIRE is a single-center prospective longitudinal observational study investigating the IHD outcome of NGT subjects who underwent coronary revascularization by PCI in a third level cardiology center at A.O. dei Colli Hospital, University of Campania "Luigi Vanvitelli". Six hundred seventy-nine subjects hospitalized in 2015 for coronary arteriography not suffering from Acute Coronary Syndrome (ACS) in the previous 4 weeks, as well as from all conditions could affect glycemic plasma levels and IR status, were assessed for eligibility. Fifty-four patients with neither history of diabetes nor Altered Fasting Glucose (AFG)/Impaired Fasting Glucose (IGT) after Oral Glucose Tolerance Test (OGTT) were finally enrolled. Primary endpoint was the assessment of the relationship of adipokines and HOMA-IR with the occurrence of restenosis in NGT subjects. As secondary endpoint we assessed the association of the same adipokines and IR with overall ACS events after PCI in NGT subjects. RESULTS: The 54 NGT patients enrolled were mainly males (85%), with a median age of 60 years [IQR 58-63 years]. Only 4 patients (7.4%) experimented restenosis. Median follow-up was equal to 29.5 months [IQR 14.7-34 months]. Adiponectin levels were independently associated to restenosis (OR 0.206; 95% CI 0.053-0.796; p = 0.000). Instead HOMA-IR and adiponectin appeared independently associated both to de novo IHD (OR 9.6*10 CONCLUSION: IR and cytokines play a role in progression of any stage of IHD also in NGT subjects. Our results in this setting of patients, though the relatively small sample size, represent a novelty. Future studies on larger populations are needed to analyze more in depth adipokines and insulin resistance role on IHD progression in non-diabetic people.

6 Article Characteristics, treatment and quality of life of stable coronary artery disease patients with or without angina: Insights from the START study. 2018

De Luca, Leonardo / Temporelli, Pier Luigi / Lucci, Donata / Colivicchi, Furio / Calabrò, Paolo / Riccio, Carmine / Amico, Antonio / Mascia, Franco / Proia, Emanuele / Di Lenarda, Andrea / Gulizia, Michele Massimo / Anonymous790998. ·Division of Cardiology, S. Giovanni Evangelista Hospital, Tivoli (Roma), Italy. · Division of Cardiology, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno (Novara), Italy. · ANMCO Research Center, Firenze, Italy. · Division of Cardiology, S. Filippo Neri Hospital, Roma, Italy. · Department of Cardiology, Azienda Ospedaliera Sant'Anna e San Sebastiano, Caserta, Italy. · Division of Cardiology, S. Giuseppe Hospital, Copertino (Lecce), Italy. · Division of Cardiology Ave Gratia Plena Hospital, Piedimonte Matese (Caserta) Italy. · Cardiology, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy. · Division of Cardiology, Garibaldi-Nesima Hospital, Catania, Italy. ·PLoS One · Pubmed #30001355.

ABSTRACT: Data on contemporary management patterns of angina in patients with stable coronary artery disease (CAD) are scarce. We sought to describe the current presentation, management, and quality of life of stable CAD patients with or without angina, using the data from the START (STable Coronary Artery Diseases RegisTry) study. START was a prospective, observational, nationwide study aimed to evaluate the presentation, management, treatment and quality of life of stable CAD presenting to cardiologists during outpatient visits or discharged from cardiology wards. Among the 5070 consecutive stable CAD patients enrolled in 183 participating centers over a 3-month period, 3714 (73.2%) had no angina and 1356 (26.8%) presented with angina. Patients with angina underwent more frequently coronary angiography (92.7% vs 84.9%; p<0.0001) and other diagnostic imaging procedures compared to those without angina. In addition, patients with angina received more frequently different combinations of first line therapies and angina relief drugs compared to patients without angina. The quality of life, assessed with the EQ 5D-5L questionnaire, did not differ between the two groups, with the exception of the 'pain or worry' domain that was higher in patients with compared to those without angina (p<0.0001). Current management and treatment of stable CAD patients with angina is still suboptimal and different compared to those without angina. Our findings highlight the need for disseminating best-practice patterns and improving guidelines adherence for the management of angina even among cardiologists.

7 Article Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry). 2017

Cortese, Bernardo / Ielasi, Alfonso / Moscarella, Elisabetta / Loi, Bruno / Tarantini, Giuseppe / Pisano, Francesco / Durante, Alessandro / Pasquetto, Giampaolo / Colombo, Alessandro / Tumminello, Gabriele / Moretti, Luciano / Calabrò, Paolo / Mazzarotto, Pietro / Varricchio, Attilio / Tespili, Maurizio / Latini, Roberto A / Defilippi, Gianfranco / Corrado, Donatella / Steffenino, Giuseppe / Anonymous3030904. ·Division of Cardiology, ASST Fatebenefratelli-Sacco, "Fatebenefratelli" Hospital, Milan, Italy; Fondazione Monasterio-Centro Nazionale delle Ricerche-Regione Toscana, Massa, Italy. Electronic address: bcortese@gmail.com. · Division of Cardiology, ASST Bergamo Est, "Bolognini" Hospital, Seriate (BG), Italy. · Department of Cardio-Thoracic Science, Presidio Ospedaliero "Monaldi", Azienda Ospedaliera Dei Colli, Napoli, Italy. · Department of Cardiovascular Sciences, "Brotzu" Hospital, Cagliari, Italy. · Department of Cardiac, Thoracic, and Vascular Sciences, University Hospital of Padua, Padua, Italy. · Division of Cardiology, "Parini" Regional Hospital, Aosta, Italy. · Division of Cardiology, "Valduce" Hospital, Como, Italy. · Division of Cardiology, "Riuniti Hospital Padova Sud", Monselice (PD), Italy. · Division of Cardiology, ASST Fatebenefratelli-Sacco, "Sacco" Hospital, Milan, Italy. · Division of Cardiology, "Cardinal Massaia" Hospital, Asti, Italy. · Division of Cardiology, "Mazzoni" Hospital, Ascoli Piceno, Italy. · Division of Cardiology, Second University of Naples, "Monaldi" Hospital, Naples, Italy. · Division of Cardiology, Azienda Socio-Sanitaria Territoriale di Lodi, Lodi, Italy. · Division of Cardiology, ASST Fatebenefratelli-Sacco, "Fatebenefratelli" Hospital, Milan, Italy. · "Istituto di Ricerche Farmacologiche Mario Negri", Milan, Italy. · Interventional Cardiology Unit, "Santa Croce e Carle" Hospital, Cuneo, Italy. ·Am J Cardiol · Pubmed #28438304.

ABSTRACT: The Absorb biovascular scaffold (BVS) is a bioresorbable, everolimus-eluting scaffold whose data on real-world patients with complex lesions are limited. Short-term follow-up from recent studies point to a higher rate of 30-day thrombosis than observed with drug-eluting stents. We aimed to understand the short-term safety and efficacy of BVS. Registro Absorb Italiano (RAI, ClinicalTrials.gov:NCT02298413) is an Italian, prospective, multicenter registry not funded, whose aim is to investigate BVS performance through a 5-year follow-up of all consecutive patients who have undergone successful implantation of ≥1 BVS in different clinical/lesion subsets. Co-primary end points were target lesion revascularization and definite/probable thrombosis. Secondary end point was the occurrence of device-oriented cardiac events. The registry involved 23 centers, with patient enrollment from October 2012 to December 2015. We here report the 30-day outcomes of the whole population of the registry. We enrolled 1,505 consecutive patients, of which 82% were men and 22.4% diabetic. At presentation, 59.6% of the patients had an acute coronary syndrome, including 21% ST-elevation myocardial infarction. All lesions were pre-dilated and in 96.8% of the cases BVS was post-dilated. At 30 days, the co-primary study end point target lesion revascularization occurred in 0.6% of patients and definite/probable BVS thrombosis in 0.8%. There were 2 cases of cardiac and overall death (0.13%). Device-oriented cardiac events occurred in 1% of the patients. In conclusion, our data of consecutive patients suggest that current use of BVS in a wide spectrum of coronary narrowings and clinical settings is associated with good outcome at 30 days.

8 Article Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry. 2017

Rubboli, Andrea / Saia, Francesco / Sciahbasi, Alessandro / Leone, Antonio M / Palmieri, Cataldo / Bacchi-Reggiani, Maria Letizia / Calabrò, Paolo / Bordoni, Barbara / Piccalò, Giacomo / Franco, Nicoletta / Nicolino, Annamaria / Magnavacchi, Paolo / Vignali, Luigi / Mameli, Stefano / Dallago, Michele / Maggiolini, Stefano / Steffanon, Luigi / Piovaccari, Giancarlo / Di Pasquale, Giuseppe / Anonymous8150901. ·Division of Cardiology - Laboratory of Interventional Cardiology, Ospedale Maggiore, Bologna, Italy. Electronic address: andrearubboli@libero.it. · Cardio-Thoraco-Vascular Department, University Hospital S. Orsola-Malpighi, Bologna, Italy. · Unit of Interventional Cardiology, Ospedale Sandro Pertini, Roma, Italy. · Department of Cardiovascular Sciences, Università Cattolica del Sacro Cuore, Roma, Italy. · Division of Interventional Cardiology, Ospedale del Cuore G. Pasquinucci, Massa, Italy. · Division of Cardiology, Seconda Università, Ospedale Monaldi, Napoli, Italy. · Division of Cardiology 1, Ospedale Niguarda, Milano, Italy. · Division of Cardiology, Ospedale degli Infermi, Rimini, Italy. · Division of Cardiology, Ospedale S. Corona, Pietra Ligure, Italy. · Division of Cardiology, Ospedale Civile S. Agostino Estense, Modena, Italy. · Division of Cardiology, Azienda Ospedaliera-Universitaria, Parma, Italy. · Division of Cardiology, Ospedale S. Francesco, Nuoro, Italy. · Division of Cardiology, Ospedale S. Chiara, Trento, Italy. · Division of Cardiology, Ospedale S. Leopoldo Mandic, Merate, Italy. · Unit of Cardiac and Vascular interventions, Hesperia Hospital, Modena, Italy. · Division of Cardiology - Laboratory of Interventional Cardiology, Ospedale Maggiore, Bologna, Italy. ·Cardiovasc Revasc Med · Pubmed #28363682.

ABSTRACT: PURPOSE: To evaluate the outcome of patients with an established indication for oral anticoagulation (OAC) undergoing coronary stent implantation (PCI-S) and stratified by the baseline risk of bleeding. MATERIAL AND METHODS: The database of the prospective, multicentre, observational WAR-STENT registry (ClinicalTrials.gov identifier NCT00722319) was analyzed and patients with atrial fibrillation and CHA RESULTS: At 12-month follow up, MACVE were comparable in the two groups, whereas total, major and minor bleeding, as well as combined MACVE and total bleeding, were significantly more frequent in the non-low bleeding risk group. Upon Cox univariate and multivariable analysis, non-low bleeding risk category confirmed as an independent predictor of major bleeding. The choice of antithrombotic therapy however, appeared not to be influenced by the bleeding risk category at baseline. CONCLUSIONS: In patients with an established indication for OAC undergoing PCI-S, non-low bleeding risk category is the most potent independent predictor of major bleeding. Stratification of the bleeding risk at baseline should therefore be regarded as an indispensable process to be carried out before selection of the antithrombotic therapy.

9 Article Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. 2016

Briguori, Carlo / Madonna, Rosalinda / Zimarino, Marco / Calabrò, Paolo / Quintavalle, Cristina / Salomone, Maria / Condorelli, Gerolama / De Caterina, Raffaele. ·Clinica Mediterranea, Naples, Italy. · Institute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University - Chieti, C/o Ospedale SS. Annunziata, Via dei Vestini, 66013, Chieti, Italy. · Department of Cardiothoracic Sciences, Monaldi Hospital, Second University of Naples, Naples, Italy. · Department of Molecular Medicine and Medical Biotechnologies, "Federico II" University of Naples, Naples, Italy. · Dimensione Ricerca, Milan, Italy. · ES Health Science Foundation, Lugo, Italy. · Institute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University - Chieti, C/o Ospedale SS. Annunziata, Via dei Vestini, 66013, Chieti, Italy. rdecater@unich.it. ·Cardiovasc Drugs Ther · Pubmed #27358173.

ABSTRACT: BACKGROUND: Periprocedural myocardial infarction (MI) is a frequent complication of percutaneous coronary intervention (PCI). Statins might reduce its incidence. The aims of the present study are to assess whether such benefit is a class-effect or whether differences exist between various lipid-lowering strategies and whether cardioprotection is exerted by increasing circulating endothelial progenitor cells (EPCs). METHODS: The REMEDY study will enroll a total of 1080 patients submitted to elective PCI. Eligible patients will be randomized into 4 groups: 1) placebo; 2) atorvastatin (80 mg + 40 mg before PCI); 3) rosuvastatin (40 mg twice before PCI); and 4) rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI. Peri-procedural MI is defined as an elevation of markers of cardiac injury (either CK-MB or troponin I or T) values >5x the upper reference limit estimated at the 99th percentile of the normal distribution, or a rise >20 % in case of baseline values already elevated. EPCs will be assessed before, at 24 h and - in a subset of diabetic patients - at 3 months after PCI (EPC-substudies). The primary endpoint of the main REMEDY study is the rate of peri-procedural MI in each of the 4 treatment arms. Secondary endpoints are the combined occurrence of 1-month major adverse events (MACE, including death, MI, or the need for unplanned revascularization); and any post-procedural increase in serum creatinine. Endpoints of the EPC-substudies are the impact of tested regimens on 1) early (24-h) and 3-month EPC levels and functional activity; 2) stent strut re-endothelialization and neointimal hyperplasia; 3) 1-year MACE. REMEDY will add important information on the cardioprotective effects of statins after PCI.

10 Article Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors polymorphisms? 2015

Vriz, Olga / Minisini, Rosalba / Zito, Concetta / Boccato, Elisa / Fimiani, Fabio / Pirisi, Mario / Facciolo, Caterina / Limongelli, Giuseppe / Bossone, Eduardo / Calabrò, Paolo. ·Department of Emergency and Cardiology, S. Antonio Community Hospital, San Daniele del Friuli (UD), Italy. Electronic address: olgavriz@yahoo.com. · Department of Translational Medicine, University of Eastern Piedmont "A. Avogadro", Novara, Italy. · Clinical and Experimental Department of Medicine and Pharmacology, University of Messina, Messina, Italy. · Cardiology SUN, Monaldi Hospital, Second University of Naples, Naples, Italy. · Cardiac Surgery Department, IRCCS Policlinico San Donato, Milan, Italy. ·Int J Cardiol · Pubmed #26197406.

ABSTRACT: AIM: Catecholamine excess along with an exaggerated sympathetic stimulation appears to play a major role in the pathophysiological mechanism of tako-tsubo cardiomyopathy (TTC), which mimics acute ST-elevation myocardial infarction (STEMI). The aim of the present study was to investigate differences in the distribution of allelic variants of β1- and β2-adrenoceptors between TTC and anterior STEMI patients compared to normal subjects. METHODS AND RESULTS: β1- and/or β2-adrenoceptor polymorphisms in 97 patients with TTC (92 females, 96%; mean age 66.8±11.6years; range 35 to 87years) were compared with 81 patients with anterior STEMI (77 females, 95%; mean age 72.5±12.8years; range 32 to 96years) and 101 controls (95 females, 94%; mean age 62.3±10.4years; range 44 to 92years). Differences in genotype frequencies were assessed using the Pearson χ(2) test. β1-Adrenoceptor (Gly389Arg) and β2-adrenoceptor (Arg16Gly and Gln27Glu) genotype frequencies were significantly different among groups (p<0.001, p=0.024, p=0.008, respectively). However, differences did not achieve statistical significance when TTC and anterior STEMI patients were compared by post-hoc analysis. The cardiovascular risk factor profile was worse in anterior STEMI patients, who more often had a history of systemic arterial hypertension, diabetes and coronary artery disease. CONCLUSIONS: In a large TTC cohort compared with anterior STEMI patients, β-adrenoceptor polymorphisms were similar. However, the cardiovascular risk factor profile was different between the two groups. β-Adrenoceptor polymorphisms in TTC patients differed from normal subjects.

11 Article Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. 2015

Costa, Francesco / Vranckx, Pascal / Leonardi, Sergio / Moscarella, Elisabetta / Ando, Giuseppe / Calabro, Paolo / Oreto, Giuseppe / Zijlstra, Felix / Valgimigli, Marco. ·Thoraxcenter, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands Department of Clinical and Experimental Medicine, Policlinico 'G. Martino', University of Messina, Italy. · Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium. · Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia, Italy. · Division of Cardiology, Department of Cardiothoracic Sciences, Second University of Naples, Naples, Italy. · Department of Clinical and Experimental Medicine, Policlinico 'G. Martino', University of Messina, Italy. · Thoraxcenter, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands. · Thoraxcenter, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands m.valgimigli@erasmusmc.nl vlgmrc@unife.it. ·Eur Heart J · Pubmed #25718355.

ABSTRACT: AIMS: We investigated if acute coronary syndrome (ACS) rather than stable coronary artery disease (SCAD) presentation is an outcome modifier with respect to the duration of dual-antiplatelet therapy (DAPT) in patients undergoing coronary stenting. METHODS AND RESULTS: In the Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia (PRODIGY) trial, a total of 1465 (74.3%) patients presented ACS whereas 505 (25.7%) had SCAD and were randomized to 6- or 24-month DAPT. At 24 months, the composite of death, myocardial infarction (MI), or cerebrovascular accident (CVA) did not differ between the long- and short-term DAPT arms in both ACS (11.1 vs. 11.7%; P = 0.67) and SCAD (7.5 vs. 4.8%; P = 0.21) patients, respectively. Long-term DAPT was associated with a 75% increase of Bleeding Academic Research Consortium (BARC)-class 2, 3, or 5 bleeding in ACS [7.1 vs. 4.1%; hazard ratio (HR) 1.75, 95% confidence interval (CI) 1.11-2.74, P = 0.015; number needed to treat for harm (NNTH): 33.3] and a five-fold increase in SCAD (8.2 vs. 1.6%; HR 5.37, 95% CI 1.84-15.74, P = 0.002; NNTH: 15.1) patients, with a borderline quantitative interaction (PINT = 0.056). As a result, net adverse cardiovascular events (death, MI, CVA, BARC class 2, 3, or 5 bleeding) were more than doubled in SCAD patients receiving 24-month DAPT, whereas they did not differ in ACS patients (PINT = 0.024). CONCLUSIONS: This analysis suggests that clinical presentation may be a treatment modifier with respect to DAPT duration after stenting consistent with the hypothesis that SCAD-but not ACS-patients are exposed to a significant increase in bleeding and net adverse clinical events when treated with 24-month compared with 6-month therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00611286. http://clinicaltrials.gov/ct2/show/NCT00611286?term=prodigy&rank=2.

12 Article Clinical outcome in patients with intermediate stenosis of left anterior descending coronary artery after deferral of revascularization on the basis of noninvasive coronary flow reserve measurement. 2009

D'Andrea, Antonello / Severino, Sergio / Mita, Claudia / Riegler, Lucia / Cocchia, Rosangela / Gravino, Rita / Castaldo, Francesca / Scarafile, Raffaella / Salerno, Gemma / Pirone, Sergio / Calabrò, Paolo / Bigazzi, Maurizio Cappelli / Citro, Rodolfo / Cuomo, Sergio / Caso, Pio / Calabrò, Raffaele. ·Chair of Cardiology, Second University of Naples, Via G. Martucci 35, Naples, Italy. antonellodandrea@libero.it ·Echocardiography · Pubmed #19054024.

ABSTRACT: BACKGROUND: Several reports suggest that noninvasive measurements of coronary flow reserve (CFR) by use of echocardiography may support decision making in intermediate stenosis of the left anterior descending coronary artery (LAD). The aim of the present study was therefore to analyze the clinical outcome in patients with intermediate stenosis of LAD after deferral of coronary revascularization on the basis of noninvasive CFR measurement. METHODS: the study population included 280 patients with intermediate LAD stenosis (50-70% by angiography) (62.2 +/- 9.6 years). All the patients underwent transthoracic CFR assessment of LAD (after dipyridamole infusion) within 2 weeks from coronary angiography. If CFR of LAD was < or = 2, PTCA was recommended; if CFR was > 2, medical treatment was chosen. Primary end points were cardiac death, myocardial infarction, coronary revascularization procedure, and unstable angina. RESULTS: mean follow-up was 43 +/- 11 months (range 12-52 months). In 150 patients (53.6%) (CFR < or = 2), coronary artery revascularization was performed (PTCA group); the remaining 130 patients (46.4%) (CFR > 2) were medically treated (medical group). Survival from cardiac death was 94% in the PTCA group and 92.4% in the medical group (P = 0.56). As for all cardiac events, the Kaplan-Meier percentage survival from cardiac events was 88.3% in the PTCA group and 86.4% in the medical group (P = 0.36). CONCLUSIONS: even if CFR as a "stand-alone" diagnostic criterion suffers from several structural limitations, a combined strategy including also other clinical and instrumental measurements before undergoing interventional procedures could improve the cost-benefit practice, in particular, for the management of patients with intermediate LAD stenosis.

13 Minor Contemporary evidence of coronary atherosclerotic disease and myocardial bridge on left anterior descending artery in a patient with a nonobstructive hypertrophic cardiomyopathy. 2011

Calabrò, Paolo / Bianchi, Renatomaria / Caprile, Mario / Bigazzi, Maurizio Cappelli / Sordelli, Chiara / Palmieri, Rosalinda / D'Alessandro, Raffaella / Golia, Enrica / Limongelli, Giuseppe / Pacileo, Giuseppe / Calabrò, Raffaele. · ·J Cardiovasc Med (Hagerstown) · Pubmed #19858731.

ABSTRACT: -- No abstract --